Tuesday, June 18

Psilocybin-assisted therapy may provide more cost-effective solution to treating major depression disorder

A new study by leading academics in the psychedelics space finds that psilocybin combined with therapy could be more cost-effective at treating major depression disorders than currently used methods.

The study, ‘Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model’, published by Cambridge University Press, found that when psilocybin was costed at £1200 and combined with therapy from one therapist, the cost of treatment was £5239.

Psilocybin-based treatment was also found to provide stronger returns in terms of the quality of life of patients following treatment, with psilocybin’s treatment returning a QALY nearly 10% larger than the next most effective treatment, CBT.

Read more at News Medical Life Sciences